Sight Sciences, Inc., an ophthalmic medical device company, engages the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology, for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
IPO Year: 2021
Exchange: NASDAQ
Website: sightsciences.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/6/2024 | $5.50 | Buy | UBS |
| 11/4/2024 | $10.00 → $5.00 | Buy → Hold | Lake Street |
| 8/21/2024 | $10.00 | Buy | Lake Street |
| 9/12/2023 | $10.00 → $4.50 | Neutral → Underperform | BofA Securities |
| 9/12/2023 | $15.00 → $5.50 | Overweight → Neutral | Piper Sandler |
| 9/12/2023 | Outperform → Mkt Perform | William Blair | |
| 8/24/2023 | $12.00 → $8.40 | Overweight → Equal-Weight | Morgan Stanley |
| 7/10/2023 | $15.00 → $9.00 | Buy → Neutral | Citigroup |
| 1/6/2023 | $10.00 → $15.00 | Hold → Buy | Stifel |
| 10/4/2022 | Hold | Needham |
4 - Sight Sciences, Inc. (0001531177) (Issuer)
4 - Sight Sciences, Inc. (0001531177) (Issuer)
4 - Sight Sciences, Inc. (0001531177) (Issuer)
4 - Sight Sciences, Inc. (0001531177) (Issuer)
4 - Sight Sciences, Inc. (0001531177) (Issuer)
4 - Sight Sciences, Inc. (0001531177) (Issuer)
4 - Sight Sciences, Inc. (0001531177) (Issuer)
3 - Sight Sciences, Inc. (0001531177) (Issuer)
4 - Sight Sciences, Inc. (0001531177) (Issuer)
4 - Sight Sciences, Inc. (0001531177) (Issuer)
4 - Sight Sciences, Inc. (0001531177) (Issuer)
4 - Sight Sciences, Inc. (0001531177) (Issuer)
4 - Sight Sciences, Inc. (0001531177) (Issuer)
4 - Sight Sciences, Inc. (0001531177) (Issuer)
4 - Sight Sciences, Inc. (0001531177) (Issuer)
4 - Sight Sciences, Inc. (0001531177) (Issuer)
4 - Sight Sciences, Inc. (0001531177) (Issuer)
4 - Sight Sciences, Inc. (0001531177) (Issuer)
4 - Sight Sciences, Inc. (0001531177) (Issuer)
4 - Sight Sciences, Inc. (0001531177) (Issuer)
SC 13G/A - Sight Sciences, Inc. (0001531177) (Subject)
SC 13G/A - Sight Sciences, Inc. (0001531177) (Subject)
SC 13G - Sight Sciences, Inc. (0001531177) (Subject)
SC 13G/A - Sight Sciences, Inc. (0001531177) (Subject)
SC 13D/A - Sight Sciences, Inc. (0001531177) (Subject)
SC 13G/A - Sight Sciences, Inc. (0001531177) (Subject)
SC 13G/A - Sight Sciences, Inc. (0001531177) (Subject)
SC 13G - Sight Sciences, Inc. (0001531177) (Subject)
SC 13D/A - Sight Sciences, Inc. (0001531177) (Subject)
SC 13D/A - Sight Sciences, Inc. (0001531177) (Subject)
8-K - Sight Sciences, Inc. (0001531177) (Filer)
SD - Sight Sciences, Inc. (0001531177) (Filer)
10-Q - Sight Sciences, Inc. (0001531177) (Filer)
8-K - Sight Sciences, Inc. (0001531177) (Filer)
DEFA14A - Sight Sciences, Inc. (0001531177) (Filer)
DEF 14A - Sight Sciences, Inc. (0001531177) (Filer)
8-K - Sight Sciences, Inc. (0001531177) (Filer)
10-K - Sight Sciences, Inc. (0001531177) (Filer)
8-K - Sight Sciences, Inc. (0001531177) (Filer)
8-K - Sight Sciences, Inc. (0001531177) (Filer)
UBS initiated coverage of Sight Sciences with a rating of Buy and set a new price target of $5.50
Lake Street downgraded Sight Sciences from Buy to Hold and set a new price target of $5.00 from $10.00 previously
Lake Street initiated coverage of Sight Sciences with a rating of Buy and set a new price target of $10.00
BofA Securities downgraded Sight Sciences from Neutral to Underperform and set a new price target of $4.50 from $10.00 previously
Piper Sandler downgraded Sight Sciences from Overweight to Neutral and set a new price target of $5.50 from $15.00 previously
William Blair downgraded Sight Sciences from Outperform to Mkt Perform
Morgan Stanley downgraded Sight Sciences from Overweight to Equal-Weight and set a new price target of $8.40 from $12.00 previously
Citigroup downgraded Sight Sciences from Buy to Neutral and set a new price target of $9.00 from $15.00 previously
Stifel upgraded Sight Sciences from Hold to Buy and set a new price target of $15.00 from $10.00 previously
Needham initiated coverage of Sight Sciences with a rating of Hold
MENLO PARK, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced plans to present at the Stifel 2025 Virtual Ophthalmology Forum. Sight Sciences' management is scheduled to present on Tuesday, May 27, 2025, at 09:00 am PT / 12:00 pm ET. Interested parties may access a live and archived webcast of the fireside chat on the Investors section of the Company's website at https://investors.sightsciences.com/. About Sight Sciences Sight Sciences is an eyecar
MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the first quarter ended March 31, 2025, reaffirms revenue guidance for full year 2025, and announces improved adjusted operating expenses guidance for full year 2025. Recent Financial and Business Highlights Generated first quarter 2025 total revenue of $17.5 million, a decrease of 9% compared to the same period in the prior year. This decline was primarily due to lower revenue from the Company's
MENLO PARK, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will report financial results for the first quarter ended March 31, 2025, after the market close on Thursday, May 8, 2025. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at
MENLO PARK, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today that it has published its annual Sustainability Report, highlighting the Company's sustainability activities, performance and results from the last three years. "We are proud to issue our second Sustainability Report, showing our commitment to corporate sustainability initiatives and enhanced disclosures, including our first disclosures on emissions," stated Paul Badawi, co-founder and Chief Executive Officer of Sight Sciences. "We are foc
MENLO PARK, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today that Gerhard (Gary) F. Burbach was appointed to the Company's Board of Directors on April 21, 2025. Mr. Burbach will serve as a Class II director with a term expiring at the 2026 Annual Meeting of Stockholders. "We are very excited to add Gary to our Board of Directors," stated Paul Badawi, Co-founder and Chief Executive Officer of Sight Sciences. "He brings a strong medtech industry background with a pro
MENLO PARK, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) , an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform eye care and improve patients' lives, today announced the expansion of the OMNI® product family by launching the OMNI® Edge Surgical System. The new technology will debut at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, taking place April 25–27 in Los Angeles, California. OMNI Edge with TruSync™ technology builds on the proven performance of the OMNI® Surgical System and introduces a higher-capacity viscoelastic delivery feature
MENLO PARK, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced plans to present at the 24th Annual Needham Healthcare Conference being held virtually. Sight Sciences' management is scheduled to present on Tuesday, April 8, 2025, at 12:45 pm PT / 3:45 pm ET. Interested parties may access a live and archived webcast of the fireside chat on the "Investors" section of the Company's website at https://investors.sightsciences.com/. About Sight Sc
MENLO PARK, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today reported financial results for the fourth quarter and full year ended December 31, 2024 and initiated financial guidance for full year 2025. Recent Financial Highlights Generated fourth quarter 2024 total revenue of $19.1 million, an increase of 2% compared to the same period in the prior year, and full year 2024 total revenue of $79.9 million, a decrease of 1% compared to full year 2023.Achieved total gross marg
A Meta-Analysis of 22 Studies, and Data from the IRIS® Registry Highlighting Clinical Outcomes in Real-World Clinical Practice, Demonstrates Significant, Long-Term IOP Reduction and Medication Reduction with the OMNI® Surgical System MENLO PARK, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform eye care and improve patients' lives, today announced that multiple presentations on the OMNI® Surgical System ("OMNI") will be presented at the 2025 American Glaucoma Society ("AGS") Annual Meeting in W
MENLO PARK, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today announced it will report financial results for the fourth quarter and full year ended December 31, 2024, after the market close on Wednesday, March 5, 2025. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the even
MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the first quarter ended March 31, 2025, reaffirms revenue guidance for full year 2025, and announces improved adjusted operating expenses guidance for full year 2025. Recent Financial and Business Highlights Generated first quarter 2025 total revenue of $17.5 million, a decrease of 9% compared to the same period in the prior year. This decline was primarily due to lower revenue from the Company's
MENLO PARK, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will report financial results for the first quarter ended March 31, 2025, after the market close on Thursday, May 8, 2025. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at
MENLO PARK, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today reported financial results for the fourth quarter and full year ended December 31, 2024 and initiated financial guidance for full year 2025. Recent Financial Highlights Generated fourth quarter 2024 total revenue of $19.1 million, an increase of 2% compared to the same period in the prior year, and full year 2024 total revenue of $79.9 million, a decrease of 1% compared to full year 2023.Achieved total gross marg
MENLO PARK, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today announced it will report financial results for the fourth quarter and full year ended December 31, 2024, after the market close on Wednesday, March 5, 2025. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the even
MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today reported financial results for the third quarter ended September 30, 2024, and updated its adjusted operating expenses guidance for full year 2024. Third Quarter 2024 Financial and Business Highlights Generated total revenue of $20.2 million, an increase of 1% compared to the same period in the prior year.Generated positive cash flow of $0.4 million, a substantial improvement compared to $10.0 million cash used in
MENLO PARK, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced it will report financial results for the third quarter ended September 30, 2024, after the market close on Thursday, November 7, 2024. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.sightsci
MENLO PARK, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today reported financial results for the second quarter ended June 30, 2024, and narrowed financial guidance for full year 2024. Recent Business and Second Quarter 2024 Financial Highlights Generated total revenue of $21.4 million, an increase of 11% compared to the prior quarter and a decrease of 9% compared to the same period in the prior year.Achieved total gross margin of 86%
MENLO PARK, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced it will report financial results for the second quarter ended June 30, 2024, after the market close on Thursday, August 1, 2024. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.sightsciences.
MENLO PARK, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today reported financial results for the first quarter ended March 31, 2024, and reaffirmed financial guidance for full year 2024. Recent Business and Financial Highlights Generated first quarter 2024 total revenue of $19.3 million, an increase of 2% compared to the same period in the prior year.Achieved total gross margin of 86% in the first quarter of 2024 compared to 84% in the same period in the prior year.Reduced ca
MENLO PARK, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced it will report financial results for the first quarter ended March 31, 2024, after the market close on Thursday, May 2, 2024. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.sightsciences.co
MENLO PARK, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today that Gerhard (Gary) F. Burbach was appointed to the Company's Board of Directors on April 21, 2025. Mr. Burbach will serve as a Class II director with a term expiring at the 2026 Annual Meeting of Stockholders. "We are very excited to add Gary to our Board of Directors," stated Paul Badawi, Co-founder and Chief Executive Officer of Sight Sciences. "He brings a strong medtech industry background with a pro
MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today the appointment of MK Raheja, Ph.D. as its Executive Vice President, Research and Development, and Brenton Taylor as its Executive Vice President, Operations, effective November 4, 2024. Sight Sciences also announced that Sam Park, its Chief Operating Officer, who oversaw both R&D and Operations, will be retiring from his role at the Company effective November 15, 2024, and will remain available as a con
MENLO PARK, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today announced the appointment of Matthew Link as its Chief Commercial Officer, effective September 11, 2023. "We are very excited to have Matt join Sight Sciences as we scale our Surgical Glaucoma and Dry Eye businesses. Matt is a highly talented medtech business leader with a track record of success in transforming treatment paradigms with disruptive new technology, and predictably scaling in a public high-growth
MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announces the appointment of Alison "Ali" Bauerlein as its Chief Financial Officer and Treasurer, effective April 3, 2023. "I am incredibly excited to have Ali join Sight Sciences as we scale our business and drive towards profitable growth. Ali is an exceptionally talented professional with a proven track record of leading a rapidly growing medtech organization through multiple phases of growth. Her experience and talent will prov
MENLO PARK, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announces several Company updates. Preliminary Revenue ResultsThe Company is announcing preliminary unaudited financial results for the fourth quarter and year ended December 31, 2022. Fourth quarter 2022 total revenue is expected to be in the range of $20.4 million to $20.6 million, an increase of 40% compared to the prior year period and a sequential increase of 10% compared to the third quarter of 2022 at the estimated midpoint.
MENLO PARK, Calif., July 19, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announced the appointment of Tamara Fountain, M.D. to its Board of Directors, effective July 15, 2022. As part of her duties, Dr. Fountain has joined Sight Sciences' Nominating and Corporate Governance Committee. "Tamara is an accomplished ophthalmologist with both incredible clinical and academic credentials as well as significant ophthalmic leadership experience. She will provide Sight Sciences and our Board of Directors with new and valuable perspectives as we contin
MENLO PARK, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announced the appointment of Brenda Becker to its Board of Directors, effective March 15, 2022. As part of her duties, Ms. Becker has joined the Nominating and Governance Committee. Ms. Becker has more than 40 years of combined private and public sector experience focused on health policy and legislation. She currently serves as Senior Vice President, Global Government Affairs at Boston Scientific. "Brenda's four decades of public service and private sector expertise i
Holly Sheffield, Medical Technology Executive and Investment Banker Hank Plain, Serial Entrepreneur, Executive and Venture Capital Leader James Rogers, Public and Private Medical Technology Investor Imperative Care, Inc. today announced three appointments to the company's Board of Directors with the addition of Holly Sheffield, Hank Plain, and James Rogers. "We are grateful to have the guidance of Holly, Hank, and James as they bring distinctive and complementary industry leadership to Imperative Care as we continue to accelerate our development and commercialization efforts," said Fred Khosravi, Chairman and CEO of Imperative Care. "Having these high-caliber professionals join our Boar